Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 341

1.

Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.

Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL, Nussenzweig MC, Steinman RM, Seder RA.

Vaccine. 2010 Oct 21;28(45):7256-66. doi: 10.1016/j.vaccine.2010.08.098. Epub 2010 Sep 21.

2.

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.

Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG Jr.

Vaccine. 2010 Jul 12;28(31):5135-44. doi: 10.1016/j.vaccine.2009.08.046. Epub 2009 Sep 6.

PMID:
19737527
3.

Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.

Kastenmüller K, Espinosa DA, Trager L, Stoyanov C, Salazar AM, Pokalwar S, Singh S, Dutta S, Ockenhouse CF, Zavala F, Seder RA.

Infect Immun. 2013 Mar;81(3):789-800. doi: 10.1128/IAI.01108-12. Epub 2012 Dec 28.

4.

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.

Pichyangkul S, Kum-Arb U, Yongvanitchit K, Limsalakpetch A, Gettayacamin M, Lanar DE, Ware LA, Stewart VA, Heppner DG, Mettens P, Cohen JD, Ballou WR, Fukuda MM.

Infect Immun. 2008 Jan;76(1):229-38. Epub 2007 Oct 22.

5.

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.

Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF, Polhemus ME, Yadava A.

Vaccine. 2012 May 9;30(22):3311-9. doi: 10.1016/j.vaccine.2012.03.004. Epub 2012 Mar 13.

PMID:
22425788
6.

Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.

Carapau D, Mitchell R, Nacer A, Shaw A, Othoro C, Frevert U, Nardin E.

Infect Immun. 2013 Dec;81(12):4350-62. doi: 10.1128/IAI.00263-13. Epub 2013 Sep 16.

8.

IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.

Schwenk R, DeBot M, Porter M, Nikki J, Rein L, Spaccapelo R, Crisanti A, Wightman PD, Ockenhouse CF, Dutta S.

PLoS One. 2014 Oct 24;9(10):e111020. doi: 10.1371/journal.pone.0111020. eCollection 2014.

9.

Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.

Walsh DS, Gettayacamin M, Leitner WW, Lyon JA, Stewart VA, Marit G, Pichyangkul S, Gosi P, Tongtawe P, Kester KE, Holland CA, Kolodny N, Cohen J, Voss G, Ballou WR, Heppner DG Jr.

Vaccine. 2006 May 8;24(19):4167-78. Epub 2006 Mar 6.

PMID:
16574282
10.

T cell responses to repeat and non-repeat regions of the circumsporozoite protein detected in volunteers immunized with Plasmodium falciparum sporozoites.

Nardin E, Munesinghe YD, Moreno A, Clavijo P, Calle MC, Edelman R, Davis J, Herrington D, Nussenzweig RS.

Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:223-7. Review.

11.

Re-investigation of the circumsporozoite protein-based induction of sterile immunity against Plasmodium berghei infection.

Reed RC, Louis-Wileman V, Wells RL, Verheul AF, Hunter RL, Lal AA.

Vaccine. 1996 Jun;14(8):828-36.

PMID:
8817831
12.

A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.

Noe AR, Espinosa D, Li X, Coelho-Dos-Reis JG, Funakoshi R, Giardina S, Jin H, Retallack DM, Haverstock R, Allen JR, Vedvick TS, Fox CB, Reed SG, Ayala R, Roberts B, Winram SB, Sacci J, Tsuji M, Zavala F, Gutierrez GM.

PLoS One. 2014 Sep 23;9(9):e107764. doi: 10.1371/journal.pone.0107764. eCollection 2014.

13.

Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).

Udhayakumar V, Saekhou A, Fang S, Jue D, Wohlhueter RM, Lal AA.

Vaccine. 1998 May-Jun;16(9-10):982-8.

PMID:
9682348
14.

A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor.

Kumar S, Villinger F, Oakley M, Aguiar JC, Jones TR, Hedstrom RC, Gowda K, Chute J, Stowers A, Kaslow DC, Thomas EK, Tine J, Klinman D, Hoffman SL, Weiss WW.

Immunol Lett. 2002 Apr 1;81(1):13-24.

PMID:
11841841
15.

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J.

J Infect Dis. 1999 Nov;180(5):1656-64.

PMID:
10515829
16.

Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein.

Almeida AP, Dias MO, Vieira Cde A, Chávez-Olórtegui C, Gazzineli RT, Rodrigues MM, Fujiwara RT, Bruna-Romero O.

Vaccine. 2014 Apr 17;32(19):2181-7. doi: 10.1016/j.vaccine.2014.02.053. Epub 2014 Feb 28.

PMID:
24582631
17.

Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.

McCoy ME, Golden HE, Doll TA, Yang Y, Kaba SA, Zou X, Gerbasi VR, Burkhard P, Lanar DE.

Malar J. 2013 Apr 22;12:136. doi: 10.1186/1475-2875-12-136. Erratum in: Malar J. 2013;12:356. Zou, Xiaoyan [added]; Gerbasi, Vincent R [added].

19.

The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.

Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J.

Clin Vaccine Immunol. 2010 Nov;17(11):1687-94. doi: 10.1128/CVI.00311-10. Epub 2010 Sep 8. Erratum in: Clin Vaccine Immunol. 2011 Feb;18(2):353.

20.

Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.

Przysiecki C, Lucas B, Mitchell R, Carapau D, Wen Z, Xu H, Wang XM, Nahas D, Wu C, Hepler R, Ottinger E, Ter Meulen J, Kaslow D, Shiver J, Nardin E.

Front Cell Infect Microbiol. 2012 Nov 30;2:146. doi: 10.3389/fcimb.2012.00146. eCollection 2012.

Supplemental Content

Support Center